{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:49:09Z","timestamp":1776026949975,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to identify prognostic factors in patients with newly diagnosed primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate\u2013based therapy and to develop a novel risk-stratification model using easily measurable clinical and laboratory parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 451 patients with newly diagnosed PCNSL were identified from a prospective registry at Asan Medical Center, Seoul. Patients were randomly assigned to a training cohort (N\u2009=\u2009280; October 2002\u2013August 2019) and an independent validation cohort (N\u2009=\u2009171; September 2019\u2013December 2023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With a median follow-up of 106.0 months (95% CI, 101.0-120.0), the median overall survival (OS) in the training cohort was 46.1 months (95% CI, 34.9-57.6). Independent predictors of worse OS (P\u2009&amp;lt;\u20090.05) included age \u226565 years, high serum \u03b22-microglobulin levels (\u22651.8 mg\/L), elevated serum lactate dehydrogenase, and Eastern Cooperative Oncology Group (ECOG) performance status &amp;gt;1. These four factors were combined to form the ABLE score, which stratified patients into low- (0 risk factors), intermediate- (1 risk factor), and high-risk (\u22652 risk factors) groups. In the training cohort, median OS was 109.0, 49.0, and 18.0 months, respectively (P\u2009&amp;lt;\u20090.001). Validation in the independent cohort confirmed significant prognostic discrimination, with median OS of not reached, 53.1, and 19.0 months for each risk group (P\u2009&amp;lt;\u20090.001). Comparative analyses demonstrated that the ABLE model showed improved discrimination compared with existing systems. Bootstrap validation (N\u2009=\u2009451) yielded an optimism-corrected C-index of 0.656 (95% CI, 0.628-0.685).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ABLE risk-stratification model can effectively differentiate prognostic subgroups in patients with PCNSL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf275","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:31:18Z","timestamp":1764592278000},"page":"741-751","source":"Crossref","is-referenced-by-count":0,"title":["A novel prognostic model for primary central nervous system lymphoma incorporating clinico-laboratory parameters"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0403-2091","authenticated-orcid":false,"given":"Yeokyeong","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewon","family":"Hyung","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoungmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Sik","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heounjeong","family":"Go","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Hye","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-3215","authenticated-orcid":false,"given":"Minyoung","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangjoon","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-3798","authenticated-orcid":false,"given":"Sang Woo","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hyun","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Ho","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-4523","authenticated-orcid":false,"given":"Jeong Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-3462","authenticated-orcid":false,"given":"Ji Sung","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["South Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Jin","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-2795","authenticated-orcid":false,"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-3548","authenticated-orcid":false,"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2026041216244002300_noaf275-B1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026041216244002300_noaf275-B2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"2026041216244002300_noaf275-B3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"key":"2026041216244002300_noaf275-B4","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026041216244002300_noaf275-B5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/1097-0142(19940815)74:4<1383::AID-CNCR2820740432>3.0.CO;2-1","article-title":"Pathology with clinical correlations of primary central nervous system non-Hodgkin\u2019s lymphoma. The Massachusetts general hospital experience 1958-1989","volume":"74","author":"Miller","year":"1994","journal-title":"Cancer"},{"key":"2026041216244002300_noaf275-B6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0360-3016(97)00571-3","article-title":"Primary central nervous system lymphoma: age and performance status are more important than treatment modality","volume":"41","author":"Corry","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041216244002300_noaf275-B7","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","article-title":"Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European organization for research and treatment of cancer brain tumor group","volume":"21","author":"Hoang-Xuan","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026041216244002300_noaf275-B8","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026041216244002300_noaf275-B9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026041216244002300_noaf275-B10","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"key":"2026041216244002300_noaf275-B11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1084\/jem.138.6.1608","article-title":"The small subunit of HL-a antigens is beta 2-microglobulin","volume":"138","author":"Grey","year":"1973","journal-title":"J Exp Med"},{"key":"2026041216244002300_noaf275-B12","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026041216244002300_noaf275-B13","first-page":"701","article-title":"The prognostic significance of beta(2)-microglobulin in patients with Hodgkin\u2019s lymphoma","volume":"87","author":"Vassilakopoulos","year":"2002","journal-title":"Haematologica"},{"key":"2026041216244002300_noaf275-B14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00277-014-2015-2","article-title":"Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer\/T cell lymphoma","volume":"93","author":"Yoo","year":"2014","journal-title":"Ann Hematol"},{"key":"2026041216244002300_noaf275-B15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5045\/br.2014.49.3.148","article-title":"Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor","volume":"49","author":"Yoo","year":"2014","journal-title":"Blood Res"},{"key":"2026041216244002300_noaf275-B16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3109\/10428194.2014.917640","article-title":"Prognostic impact of beta(2)-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma","volume":"56","author":"Yoo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026041216244002300_noaf275-B17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5045\/br.2019.54.4.285","article-title":"Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma","volume":"54","author":"Hyung","year":"2019","journal-title":"Blood Res"},{"key":"2026041216244002300_noaf275-B18","volume-title":"Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach","author":"Burnham","year":"2002"},{"key":"2026041216244002300_noaf275-B19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat Med"},{"key":"2026041216244002300_noaf275-B20","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/sim.8135","article-title":"The power-integrated discriminant improvement: an accurate measure of the incremental predictive value of additional biomarkers","volume":"38","author":"Hayashi","year":"2019","journal-title":"Stat Med"},{"key":"2026041216244002300_noaf275-B21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bjh.17222","article-title":"A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue international prognostic index and serum beta2-microglobulin levels","volume":"193","author":"Kim","year":"2021","journal-title":"Br J Haematol"},{"key":"2026041216244002300_noaf275-B22","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2005.07.155","article-title":"Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin","volume":"23","author":"Lopez-Guillermo","year":"2005","journal-title":"JCO"},{"key":"2026041216244002300_noaf275-B23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4143\/crt.2020.1060","article-title":"Prognostic stratification of patients with burkitt lymphoma using serum beta2-microglobulin levels","volume":"53","author":"Kim","year":"2021","journal-title":"Cancer Res Treat"},{"key":"2026041216244002300_noaf275-B24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/10428194.2021.1971220","article-title":"Prognostic significance of serum beta2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified","volume":"63","author":"Kim","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026041216244002300_noaf275-B25","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041216244002300_noaf275-B26","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cam4.2872","article-title":"A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"2026041216244002300_noaf275-B27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2012.076075","article-title":"Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation","volume":"98","author":"Schorb","year":"2013","journal-title":"Haematologica"},{"key":"2026041216244002300_noaf275-B28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4103\/ajns.AJNS_208_20","article-title":"Outcome and prognostic factors of primary central nervous system lymphoma in Southern Thailand","volume":"15","author":"Sopittapan","year":"2020","journal-title":"Asian J Neurosurg"},{"key":"2026041216244002300_noaf275-B29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/ejh.14159","article-title":"Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: a retrospective, multicenter analysis of 174 patients","volume":"112","author":"Zeremski","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026041216244002300_noaf275-B30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hon.2021","article-title":"Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients","volume":"31","author":"Ghesquieres","year":"2013","journal-title":"Hematol Oncol"},{"key":"2026041216244002300_noaf275-B31","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.7150\/jca.32467","article-title":"Risk prediction for early mortality in patients with newly diagnosed primary CNS lymphoma","volume":"10","author":"Lin","year":"2019","journal-title":"J Cancer"},{"key":"2026041216244002300_noaf275-B32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"key":"2026041216244002300_noaf275-B33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40364-025-00777-z","article-title":"Reliable detection of CNS lymphoma-derived circulating tumor DNA in cerebrospinal fluid using multi-biomarker NGS profiling: insights from a real-world study","volume":"13","author":"Navrkalova","year":"2025","journal-title":"Biomark Res"},{"key":"2026041216244002300_noaf275-B34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4143\/crt.2021.752","article-title":"Plasma circulating tumor DNA in patients with primary central nervous system lymphoma","volume":"54","author":"Yoon","year":"2022","journal-title":"Cancer Res Treat"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf275\/65730142\/noaf275.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/3\/741\/65730142\/noaf275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/3\/741\/65730142\/noaf275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:24:53Z","timestamp":1776025493000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/3\/741\/8364032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf275","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,3]]}}}